IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology, Inc. announced today that interim Phase 3 monotherapy data from the BOND-003 study will be presented as a late-breaking abstract at the upcoming 24 th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback